Elicio Therapeutics Inc 9HA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $7.75
- Day Range
- $7.80–7.80
- 52-Week Range
- $3.08–14.68
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $80.11 Mil
- Volume/Avg
- 0 / 0
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 32
- Website
- https://www.elicio.com
Comparables
Valuation
|
Metric
|
9HA
|
CLDX
|
ITOS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 2.72 | 1.07 |
Price/Sales | — | 293.27 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
9HA
CLDX
ITOS
Financial Strength
|
Metric
|
9HA
|
CLDX
|
ITOS
|
|---|---|---|---|
Quick Ratio | 1.99 | 31.44 | 12.80 |
Current Ratio | 2.37 | 31.77 | 13.51 |
Interest Coverage | −51.46 | — | — |
Quick Ratio
9HA
CLDX
ITOS
Profitability
|
Metric
|
9HA
|
CLDX
|
ITOS
|
|---|---|---|---|
Return on Assets (Normalized) | −122.03% | −23.59% | −16.56% |
Return on Equity (Normalized) | — | −25.21% | −18.86% |
Return on Invested Capital (Normalized) | −179.42% | −25.04% | −22.78% |
Return on Assets
9HA
CLDX
ITOS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Cbxwstjnr | Svmml | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gjywrpjxh | Kswyzbb | $114.2 Bil | |||
| Moderna Inc
MRNA
| Wtsqxsr | Hvny | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Zzrdszk | Rvpyd | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Glngjdgzx | Fhz | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kkfpdtnl | Rngpj | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Wvmbdbhwf | Fkllpb | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Bvcrqxg | Pkj | $12.8 Bil | |||
| Incyte Corp
INCY
| Jcpfwfz | Hpdxvnn | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Txklglfk | Kpmlhk | $12.2 Bil |